Trimetazidine, a Metabolic Modulator, Has Cardiac and Extracardiac Benefits in Idiopathic Dilated Cardiomyopathy | Zendy

Helena Tuunanen | Zendy; Erik Engblom | Zendy; Alexandru Naum | Zendy; Kjell Någren | Zendy; Mika Scheinin | Zendy; Birger Hesse | Zendy; Juhani Airaksinen | Zendy; Pirjo Nuutila | Zendy; Patricia Iozzo | Zendy; Heikki Ukkonen | Zendy; Lionel H. Opie | Zendy; Juhani Knuuti | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Trimetazidine, a Metabolic Modulator, Has Cardiac and Extracardiac Benefits in Idiopathic Dilated Cardiomyopathy

Author(s) -

Helena Tuunanen,

Erik Engblom,

Alexandru Naum,

Kjell Någren,

Mika Scheinin,

Birger Hesse,

Juhani Airaksinen,

Pirjo Nuutila,

Patricia Iozzo,

Heikki Ukkonen,

Lionel H. Opie,

Juhani Knuuti

Publication year - 2008

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.108.778019

Subject(s) - trimetazidine , medicine , dilated cardiomyopathy , cardiology , cardiomyopathy , heart failure

The anti-ischemic agent trimetazidine improves ejection fraction in heart failure that is hypothetically linked to inhibitory effects on cardiac free fatty acid (FFA) oxidation. However, FFA oxidation remains unmeasured in humans. We investigated the effects of trimetazidine on cardiac perfusion, efficiency of work, and FFA oxidation in idiopathic dilated cardiomyopathy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research